Core Viewpoint - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China through integrated resources in medical services and instant retail [1][2]. Group 1: Product Launch and Features - JD Health and Kaiji Xincheng have launched the first-class innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu), which targets chronic hepatitis B treatment using HepDirectTM liver-targeting technology [1]. - The drug has received significant support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans, demonstrating its efficacy in delivering active ingredients directly to the liver, enhancing effectiveness while reducing toxicity [1]. - Phase III clinical trial results indicate that the drug shows stronger and more durable viral suppression compared to the control group, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL (P<0.05) [1]. Group 2: Nutritional Supplement - The Zinc-Selenium Multivitamin Soft Gel Capsules (brand name: Kaimumu) are designed for liver nutrition and suitable for individuals needing supplementation of zinc, selenium, and various vitamins [2]. - This product contains nine vitamins and two minerals, scientifically proportioned and packaged in soybean lecithin capsules for better absorption, with a recommended dosage of two capsules daily [2]. Group 3: Service Integration and Strategy - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to provide a comprehensive service loop, ensuring rapid dissemination of the new drugs to patients [2]. - The collaboration aims to optimize the overall patient service experience and enhance the efficiency and quality of the pharmaceutical supply chain, promoting a win-win development [2]. - JD Health is committed to providing high-quality pharmaceutical health products and services, enhancing the accessibility of innovative drugs to a broader patient population [2][3]. Group 4: Future Outlook - JD Health's value effect as the "first station for new special drug launches" continues to expand, facilitating access to cutting-edge innovative drugs through integrated online and offline channels [3]. - The company plans to collaborate with global pharmaceutical partners to improve the accessibility of new special drugs, contributing to the "Healthy China 2030" strategic goals [3].

Core Viewpoint - JD Health has entered into a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to enhance the treatment options for chronic hepatitis B patients in China [1][2]. Group 1: Partnership and Product Launch - The collaboration aims to integrate JD Health's strengths in medical services and instant retail to support clinical cure goals for chronic hepatitis B patients [1]. - The first launch of the innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu®), and Zinc-Selenium Multivitamin Soft Capsules (brand name: Kaimumu®) will be exclusive to JD Health's platform [1][2]. - Mesylate Prefofovir Tablets are designed for adult chronic hepatitis B treatment and have received significant support from national major new drug creation technology projects [1]. Group 2: Clinical Efficacy and Product Features - Phase III clinical trial results indicate that the drug effectively suppresses the virus more powerfully and durably, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) [1]. - The Zinc-Selenium Multivitamin Soft Capsules are formulated to support liver health and are rich in various vitamins and minerals, designed for easy absorption [2]. Group 3: Service Integration and Future Plans - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a comprehensive service loop for the new drugs, ensuring rapid accessibility for patients [2]. - The company plans to continue deepening strategic collaboration with Kaiji Xincheng to optimize patient service experiences and enhance the overall efficiency and quality of the pharmaceutical supply chain [2][3]. - JD Health aims to contribute to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs through partnerships with global pharmaceutical companies [3].

摘要 京东健康已成为中国最大的线上 B2C 零售药店，并积极发展 O2O 和线 下药房业务，构建了"医+药"双轮驱动的互联网医疗生态系统，未来 发展空间广阔。 京东健康背靠京东集团，在供应链和用户导流方面具备显著优势，同时 已成为创新药和新特药的首发平台，吸引了大量优质产品，提升了在患 者和药企中的认可度。 京东健康通过自营 B2C、在线平台及 O2O 业务实现全渠道布局，2025 年上半年即使线下市场不景气，仍实现了超过 20%的收入和利润增长， Non-GAAP 净利润率超过 8%。 中国处方外流和线上化趋势明显，网上药店市场销售额持续增长，B2C 互联网药店市占率显著提升，京东健康自营 B2C 业务通过快速配送和创 新产品巩固品牌优势，活跃用户数量稳步增长至 1.8 亿人次。 京东健康在线平台通过增加第三方商家数量丰富产品供给，O2O 业务覆 盖全国 20 万家药店，覆盖接近 2 亿人群，满足即时买药需求，增强市 场竞争力。 Q&A 京东健康在互联网医疗领域的地位和发展前景如何？ 京东健康是互联网医疗领域的绝对龙头企业，特别是在 AI 时代具备良好的发展 前景。自 IPO 以来，其收入从 300 亿人民 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 京东健康股份有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結存 ...

Core Viewpoint - JD Health is expected to maintain strong revenue growth and profit release in Q4 2025, driven by the continuous increase in online penetration of pharmaceutical categories and competitive advantages from its supply chain [1][2]. Group 1: Revenue and Profit Forecast - The company is projected to achieve a total revenue growth of 22.7% year-on-year in Q4 2025, reaching 20.26 billion yuan [1]. - The pharmaceutical category is expected to show robust performance with GMV growth exceeding 30%, while nutrition and medical device categories are anticipated to grow by over 20% and 10%, respectively [1]. - The company is expected to realize a non-IFRS operating profit of 260 million yuan in Q4 2025, corresponding to a non-IFRS operating profit margin of 1.3%, an improvement of 0.4 percentage points year-on-year [1]. - For the full year of 2025, JD Health's revenue is projected to grow by 25% year-on-year to 72.7 billion yuan, with a non-IFRS operating profit of 4.11 billion yuan, reflecting a non-IFRS operating profit margin of 5.7%, an improvement of 1.2 percentage points year-on-year [1]. Group 2: Offline Expansion and AI Integration - The company plans to open over 200 new offline pharmacy stores in the second half of 2025, with 150 new stores expected in Q4 2025, accelerating from over 50 in Q3 2025 [2]. - JD Health's "self-operated pharmacy medical insurance business" has expanded to 8 cities, including the recent addition of Shanghai, which is anticipated to enhance user penetration and performance [2]. - The company is strengthening collaborations with upstream medical brands for new drug launches, showcasing its increasing channel value [2]. - The AI application in healthcare is gaining traction, with the AI doctor "Dai Wei" achieving a satisfaction rate of 98%, enhancing JD Health's internet medical service capabilities [2]. Group 3: Profit Forecast and Valuation - The non-IFRS net profit forecast for 2025-2027 has been raised by 11.6%, 15.6%, and 22.4% to 6.32 billion, 7.51 billion, and 9.01 billion yuan, respectively, primarily due to revised revenue expectations [3]. - The valuation window has shifted to 2026, with a target non-IFRS PE of 30.0x for 2026, compared to a previous value of 35.0x, reflecting a premium over the average PE of comparable companies at 14.7x [3]. - The target price has been adjusted to 77.4 HKD, up from 68.3 HKD [3].

每经AI快讯，京东健康(06618.HK)午前涨超6%，截至发稿涨6.53%，报62港元，成交额4.11亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - JD Health (06618) is expected to outperform market expectations in the second half of 2025, driven by a surge in flu cases leading to increased demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's stock rose over 6%, reaching HKD 62 with a trading volume of HKD 411 million [1] - Nomura forecasts that JD Health's revenue for Q4 2025 will reach RMB 20 billion, representing a year-on-year growth of 22% [1] - The growth in Q4 2025 is attributed to sales increases in pharmaceuticals (30%), nutritional products (20%), and medical devices (10%) [1] Group 2: Market Trends - The increase in flu cases in Q4 2025 is expected to significantly boost pharmaceutical sales, contributing a high single-digit percentage to total sales [1] - The sales of medical devices, such as home oxygen concentrators, are also anticipated to rise due to the flu season [1] - Nutritional brands will continue effective marketing campaigns in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - CICC noted strong revenue performance for JD Health in 2025, with quarterly growth rates around 25% year-on-year for Q1 to Q3 [1] - The company has signed strategic cooperation agreements with pharmaceutical companies like Eli Lilly, Innovent Biologics, and Bayer China, enhancing its unique business model of launching new drugs online [1] - The ongoing trend of increasing original drug volumes is expected to support strong revenue performance in Q4 2025 [1]

Core Viewpoint - JD Health is expected to outperform market expectations in the second half of 2025, primarily due to a surge in flu cases driving up demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's revenue for Q4 2025 is projected to reach 20 billion RMB, representing a year-on-year growth of 22%, driven by sales growth in pharmaceuticals, nutritional products, and medical devices at 30%, 20%, and 10% respectively [1] - The company has shown strong revenue performance throughout 2025, with each quarter from Q1 to Q3 achieving approximately 25% year-on-year growth [1] - The overall revenue growth for JD Health in 2025 is anticipated to be close to 25% year-on-year [1] Group 2: Market Dynamics - The increase in flu cases in Q4 2025 is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - The sales of medical devices, such as home oxygen concentrators, are also expected to rise due to the flu outbreak [1] - JD Health's nutritional brands will continue to implement effective marketing strategies in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - JD Health has signed strategic cooperation agreements with pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China, enhancing its business model of launching new drugs online [1]

Core Viewpoint - JD Health's stock price has increased by 5.58%, reaching HKD 61.45, with a trading volume of HKD 230 million, driven by positive forecasts for its performance in the second half of 2025, particularly in Q4 due to a surge in flu cases increasing demand for medications [1][2] Group 1: Performance Forecasts - Nomura predicts that JD Health's Q4 2025 revenue will reach RMB 20 billion, representing a year-on-year growth of 22%, supported by sales growth of 30%, 20%, and 10% in pharmaceuticals, nutritional products, and medical devices respectively [1][2] - The report highlights that flu-related medications will account for a significant percentage of pharmaceutical sales, alongside increased sales of home medical devices like oxygen concentrators [1][2] Group 2: Revenue and Profit Adjustments - CICC has raised its revenue forecasts for JD Health for 2025 and 2026 by 2% to RMB 72.5 billion and RMB 81.7 billion respectively, considering the ongoing demand for original research products and strong flu-related product demand [1][2] - The firm has also adjusted its non-IFRS net profit estimates for 2025 and 2026 upwards by 4% and 1% to RMB 6.5 billion and RMB 6.4 billion respectively, and introduced a revenue forecast for 2027 of RMB 91.2 billion with a non-IFRS net profit forecast of RMB 6.8 billion [1][2] Group 3: Target Price and Rating - CICC maintains a target price of HKD 71.4 for JD Health, indicating a 23% upside potential, while sustaining an "outperform" rating despite recent fluctuations in the sector [1][2]

Investment Rating - The report maintains a "Buy" rating for JD Health with a target price of HKD 77.40 [7][18]. Core Insights - JD Health is expected to continue strong revenue growth in 4Q25, with a projected year-on-year increase of 22.7% to RMB 20.26 billion, driven by the increasing online penetration of pharmaceuticals and the company's competitive advantages in supply chain management [2][15]. - The company is anticipated to achieve a non-IFRS operating profit of RMB 260 million in 4Q25, reflecting a non-IFRS operating profit margin of 1.3%, an improvement of 0.4 percentage points year-on-year [2]. - The report highlights the importance of monitoring the supply iteration of new medical products, the impact of weight-loss drugs entering the medical insurance list, the penetration of AI medical applications, and the expansion of JD Health's O2O business [1]. Revenue and Profit Forecast - JD Health's total revenue for 4Q25 is expected to grow by 22.7% year-on-year to RMB 20.26 billion, with pharmaceuticals projected to see over 30% growth in GMV [2][15]. - For the full year of 2025, revenue is forecasted to increase by 25% to RMB 72.7 billion, with a non-IFRS operating profit of RMB 4.11 billion, corresponding to a non-IFRS operating profit margin of 5.7%, an improvement of 1.2 percentage points year-on-year [2][15]. Offline Business Development - JD Health is set to open over 200 new offline pharmacy stores in the second half of 2025, with 150 stores expected to open in 4Q25, enhancing user reach and brand exposure [3]. - The company's medical insurance payment coverage has expanded to 8 cities, including Shanghai, which is anticipated to drive user penetration and performance growth [3]. New Product Launches and AI Integration - JD Health continues to strengthen partnerships with upstream medical brands, achieving multiple collaborations for new drug launches, thereby enhancing its channel value [4]. - The report notes the positive reception of JD Health's AI doctor, which has achieved a satisfaction rate of 98%, reinforcing its capabilities in internet medical services [4]. Profitability Adjustments - The profit forecasts for 2025-2027 have been raised by 11.6%, 15.6%, and 22.4% respectively, due to improved revenue expectations and the anticipated release of operating leverage [5][15]. - The target valuation for 2026 has been adjusted to a non-IFRS PE of 30.0x, reflecting a premium over comparable companies, driven by JD Health's efficiency in the pharmaceutical market and its advantages in AI medical applications [18].